不同工艺芪葵颗粒对糖尿病肾病模型大鼠的保护作用

Abstract
Figure/Table
References (20)
Related Citation (5)

Download: PDF (1023 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To compare the protective effects of different processes of Qikui Particles for model rats with diabetic nephropathy. Methods Fifty-four healthy SD rats (male, 8 weeks old) were selected. The model rats with diabetic nephropathy were induced by high sugar/fat diet + unilateral nephritic ligation + Streptozotocin (STZ, 40 mg/kg, ip). After successful establishment of model rats, they were divided into 5 groups: model group, Irbesartan group, process 1 (water boiled concentrated decoction) group, process 2 (water boiled and alcohol extraction concentration) group, process 3 (the mixed of above two processes) group, and the blank group was set up. Qikui Particles prepared under 3 different processes were orally administered at the same dose (18.67 g/kg ) for 5 consecutive weeks. The effects of different processes of Qikui Particles on blood sugar, urinary protein, creatinine and endogenous creatinine clearance rate in rats with diabetic nephropathy were observed, and histopathology was detected. Results Compared with blank group, the body weight in model group was decreased significantly (P ＜ 0.01), the food-intake, water consumption and urine volume were increased (P ＜ 0.05 or P ＜ 0.01), the blood sugar was improved significantly (P ＜ 0.01). After drug intervention, compared with model group, the body weight in each drug administration group was increased more or less, the food-intake, water consumption and urine volume were decreased more or less; the blood sugar in process 2 group and process 3 group was decreased significantly (P ＜ 0.05); the serum creatinine in Irbesartan group and process 3 group was decreased significantly (P ＜ 0.05 or P ＜ 0.01); the endogenous creatinine clearance rate in each drug administration group was increased significantly (P ＜ 0.05 or P ＜ 0.01); the urinary protein excretion rate in Irbesartan group and process 2, 3 group was decreased significantly (P ＜ 0.01 or P ＜ 0.05). The results of histopathology showed that the main performance of kidney in model groups was glomerular hypertrophy, tubular dilation, interstitial and renal pelvis focal infiltration of inflammatory cells; compared with model group, the scope and extent of renal injury were reduced slightly in each drug administration group, especially in Irbesartan group and process 2 group. Conclusion The protective effects of different processes of Qikui Particles for diabetic nephropathy are related to the decrease of blood sugar, creatinine, urinary protein and alleviation of renal injury, especially in process 2 group and process 3 group.

Key words： Diabetic nephropathy Qikui Particles Blood sugar Creatinine clearance rate Urinary albumin excretion rate Histopathology

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Qing1
	2 ZHU Xuanxuan2 WANG Qiong2 LIU Zhihui2 YU Jiangyi2 YANG Chen2 FU Rui2 ZHANG Di2

Cite this article:

LIU Qing1,2 ZHU Xuanxuan2 WANG Qiong2 LIU Zhihui2 YU Jiangyi2 YANG Chen2 FU Rui2 ZHANG Di2. Protective effects of different processes of Qikui Particles for model rats with diabetic nephropathy[J]. 中国医药导报, 2017, 14(28): 25-30.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I28/25

[1] 谢绍锋，余江毅.黄蜀葵花治疗肾病研究现状[J].山西中医，2003，19（6）：45-46.
[2] 余江毅，熊宁宁，郭惠芳，等.黄蜀葵花醇提物治疗糖尿病肾病的临床观察[J].中国中西医结合杂志，1995，15：263-266.
[3] 陈璇，余江毅.玉葵清干预治疗早期2型糖尿病肾病的临床研究[J].江苏中医药，2008，40（7）：48-49.
[4] 陈璇，余江毅.玉葵清对早期2型糖尿病肾细胞因子影响的临床研究[J].浙江中医药大学学报，2009，33（1）：56-57.
[5] 王新，唐方.单侧肾脏结扎术+链脲佐菌素诱导糖尿病肾病动物模型建立方法的探讨[J].天津医科大学学报，2006， 12（1）：18-20.
[6] 李晓华，栗敏，游广辉，等.氟伐他汀对SD大鼠糖尿病肾病的保护作用[J].医学论坛杂志，2011，32（4）：12-13.
[7] 柯剑婷，李宓，姜永玮，等.格列喹酮对GK大鼠糖尿病肾病的保护作用[J].中国医院药学杂志，2013，33（10）：789-792.
[8] 王国光，张翠，陆晓华，等.核黄素对STZ诱导的大鼠糖尿病肾病的治疗作用[J].中国病理生理杂志，2010，26（7）：1395-1398.
[9] 张斌.六味地黄丸对大鼠糖尿病肾病血糖、肌酐、尿素氮影响随机平行对照研究[J].实用中医内科杂志，2013，27（5）：87，160
[10] 马祖等，曾小婷，张悦.绿茶提取物对大鼠糖尿病肾病模型的干预作用[J].南昌大学学报，2013，53（1）：21-25.
[11] 严仲庆，何敏尔，张菁，等.天合保肾合剂治疗大鼠糖尿病肾病实验研究[J].浙江中西医结合杂志，2009，19（2）：82-84.
[12] 中华中医药学会肾病分会.糖尿病肾病诊断、辩证分型及疗效评定标准[J].上海中医药杂志，2007，41（7）：7-8.
[13] 邬伟里，戴耀华.黄芪治疗早期糖尿病肾病疗效观察[J].上海医药，2000，21（3）：19-20.
[14] 陈延强，史伟，黄玉茵.糖尿病肾病中医分期辩证的探讨[J].新中医，2009，41（3）：3-4.
[15] 王光洁，张敬芳，杨雪琴.黄芪注射液治疗糖尿病肾病的实验研究[J].微循环学杂志，2007，17（1）：20-22.
[16] 陈娟，张明华，章丽，等.牡丹皮苷/酚组分对糖尿病肾病大鼠肾损伤的保护作用及其机制研究[J].中国中药杂志，2016，41（6）：1990-1998.
[17] 张雨薇，薛继婷，李齐，等.桑叶多糖对DN大鼠的保护作用及机制研究[J].中华中医药学刊，2016，34（6）：1381-1383.
[18] 樊少仪，张秀.糖尿病肾病大鼠中医气虚模型的制作及其影响因素[J].广东医学，2016，37（5）：644-647.
[19] 张孟姝，刘金磊，张春梅，等.白细胞介素-18在糖尿病肾病大鼠模型中的表达水平及其对尿液肾损伤分子-1的影响[J].中国老年学杂志，2016，36（3）：1308-1309.
[20] 常保超，陈卫东，张燕，等.白芍总苷对2型糖尿病大鼠肾组织Wnt/β-catenin信号通路表达的影响[J].中国中药杂志，2014，39（19）：3829-3835.